GKOS Stock Analysis: Buy, Sell, or Hold?
GKOS - Glaukos Corporation
$105.01
1.83 (1.77%)
▲
5d:
-1.71%
30d:
-12.78%
90d:
-9.64%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 29, 2026
29d
Smart Money Distribution
GKOS is up 4.1% this week, but smart money is buying puts. Top strike: $70 2026-05-15 with 1 OI. Put ratio: 75% View Scanner →
Strength: 4.5/10
Get Alerted When GKOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GKOS appears deeply undervalued. Market expects -3.6% annual earnings decline despite 1896% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: GKOS appears deeply undervalued. Market expects -3.6% annual earnings decline despite 1896% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.20
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$9.44
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GKOS is currently trading at $105.01, which is considered slightly low relative to its 30-day fair value range of $101.43 to $117.58. From a valuation perspective, the stock is trading at a discount (Forward PE: 237.7) compared to its historical average (265.2). Remarkably, the market is currently pricing in an annual earnings decline of 3.6% over the next few years. This pessimistic expectation contrasts with the company's recent 1896.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GKOS is in a uptrend. Immediate support is located at $98.92, while resistance sits at $110.13.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $138.75 (+34.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GKOS is in a uptrend. Immediate support is located at $98.92, while resistance sits at $110.13.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $138.75 (+34.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$101.43 -
$117.58
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.5% below Wall St target ($138.75)
Fair Price Analysis
30-Day Fair Range
$101.43 -
$117.58
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$7.23
(6.9%)
Support & Resistance Levels
Support Level
$98.92
Resistance Level
$110.13
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
237.74
Wall Street Target
$138.75
(+34.5%)
Revenue Growth (YoY)
35.7%
Earnings Growth (YoY)
1896.3%
Profit Margin
-37.0%
Valuation Discount vs History
-3.6% cheaper
PE vs Historical
237.7 vs 265.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.6%
(market-implied from PE analysis)
1-Year Target
$99.47
(-4%)
2-Year Target
$95.88
(-7%)
3-Year Target
$92.43
(-10%)
3-Yr Target (if PE normalizes)
(PE: 238→265)
$103.11
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 237.7 to 265.2
Stabilization Target:
$115.10
(+11.5%)
PE Expansion Potential:
+11.5%
Share & Embed Analysis
Last updated: March 30, 2026 4:20 PM ET
Data refreshes hourly during market hours. Next update: 5:20 PM
Data refreshes hourly during market hours. Next update: 5:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GKOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Aimee S Weisner
SELL
15000 shares
2026-02-19
Joseph E Gilliam
SELL
10498 shares
2026-01-22
Marc Stapley
SELL
15000 shares
2026-01-22
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 51 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 61 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
Advanced GKOS Option Strategies
Professional options setups generated by AI based on today's GKOS price and gamma walls.
